Physician profile
Lisa Macmaster
NPI 1518012368
$2,245.71
in general payments reported to CMS, 2019-2025
14 companies · $884 in 2025
The $884 reported for 2025 was more than what 93% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2.39 · 2022: $350 · 2023: $220 · 2024: $789 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $408.91 | 2023-2025 | |
| Dexcom, INC. | $325.20 | 2022-2025 | Dexcom G6 Transmitter |
| Genzyme Corporation | $319.84 | 2024-2025 | |
| Lilly USA, LLC | $280.40 | 2024-2025 | Kisunla, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $226.65 | 2024-2025 | Farxiga, Airsupra |
| Gilead Sciences, INC. | $202.86 | 2022-2025 | Epclusa |
| Kowa Pharmaceuticals America, INC. | $116.03 | 2022 | |
| Phathom Pharmaceuticals, INC. | $95.60 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $89.32 | 2023 | Quviviq |
| Novo Nordisk INC | $65.67 | 2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $58.29 | 2022 | |
| Exact Sciences Corporation | $37.77 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $16.78 | 2023 | M-M-R II, Gardasil 9 |
| Genentech USA, INC. | $2.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Macmaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.